Wedbush lowered the firm’s price target on Viridian Therapeutics to $39 from $40 and keeps an Outperform rating on the shares. The firm estimates Viridian’s secondary offering generates $160M in net proceeds. While the magnitude of the raise is largely as Wedbush anticipated, the timing arrives earlier than expected. It continues to assume at least two additional financings as Viridian advances its TED assets VRDN-001 and VRDN-003.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VRDN:
- Viridian Therapeutics 7.14M share Spot Secondary priced at $21.00
- Viridian announces offering of common stock, Series B preferred stock
- Spyre Therapeutics price target raised to $36 from $27 at Stifel
- Apogee Therapeutics price target raised to $46 from $34 at Stifel
- Short Report: Bears boost exposure to Rocket Companies despite dovish Fed tilt
